Wednesday 1st December 2010 at Radisson Blu Hotel, Galway City. Irish Medical Technology CEO Forum 2010 KINDLY SUPPORTED BY

Transcription

1 Wednesday 1st December 2010 at Radisson Blu Hotel, Galway City Irish Medical Technology CEO Forum 2010 KINDLY SUPPORTED BY

2 Irish Medical Technology CEO Forum 2010 Programme to Registration & Lunch to KEYNOTE SESSION: GLOBAL INSIGHTS Chair: Brian O Neill, Manager, Life Sciences, Enterprise Ireland Recognise and appreciate the effect that global trends are having on business in Ireland Understand and influence our national response to dealing with change and recovery Speakers & Panel Pat Gallagher, Outgoing Chair IMDA/ Irish Industry ins ights Pat Delaney, Director of Sectors, Enterprise and Regional Policy Roland Pfleger, VP & GM, Respiratory & Monitoring Solutions, EMEA, Covidien Bryan Mohally, Member/ Innovation Taskforce Implementation Group (VP Supply Chain Johnson & Johnson) Panel debate / Q&A 10 min 10 min 35 min 25 min 20 min to Coffee Break to EMBRACING CHANGE Chair: Gus Jones, Manager, Medical Technologies Division, IDA Ireland Hear from peers as to how they have transformed their organisations Meet and network with our industry leaders Speakers & Panel John Elwood, Vice President, Global Manufacturing, KCI Medical Matt McBride, Plant Manager, Harmac Medical Frank Keane, MD Vitalograph John Power, CEO Aerogen Panel Discussion / Q&A 15 min 15 min 15 min 15 min 25 min to Closing Remarks 5 min

3 Irish Medical Technology CEO Forum 2010 Chairs Session One and Two Brian O Neill Life Sciences, Enterprise Ireland Brian O Neill is Manager for Lifesciences at Enterprise Ireland, the agency responsible for the internationalisation of indigenous Irish industry.brian has worked for over 15 years, both nationally and internationally, in the lifesciences sector, in a variety of private sector and government roles, including basic and applied research, entrepreneur, technology transfer and business development. In his current role, Brian (and his team of dedicated functional specialists business development advisors, technologists, international marketing and human resource development experts) is responsible for the development and implementation of the strategic plan required to drive the continued global expansion of the 250+ Irish Lifesciences businesses. In addition, he also plays a key role in shaping the Irish ecosystem to ensure its long-term development and integration. Brian had a Ph.D. in Human Molecular Genetics from Trinity College Dublin and a 1st Class Honours MBA from University College Dublin. More information on Enterprise Ireland: Enterprise Ireland is the government organisation responsible for the development and growth of Irish enterprises in world markets. With 31 offices across the World, Enterprise Ireland works in partnership with Irish enterprises to help them start, grow, innovate and win export sales on global markets, supporting sustainable economic growth, regional development and secure employment. Gus Jones Manager, Medical Technologies Division Gus Jones manages IDA Ireland s Medical Technologies Division. His last assignment was to open IDA s office in China. He has wide experience of working with global companies in Information Technology, Life Sciences, International Financial Services and Digital Media companies. Previously he was based in the Boston and New York offices of IDA Ireland. Gus has a BSc degree in Computer Science from University College Cork and an MBA from University College, Dublin.

4 Irish Medical Technology CEO Forum 2010 Speakers Pat Gallagher IMDA Chairman Pat Gallagher is General Manager of Baxter Healthcare s Irish Manufacturing Operations, a position he took up in Having held various management positions with Abbott both in Ireland and overseas, Pat returned to Ireland to join Boston Scientific in Galway in 1997 before moving to Baxter to head up its Irish operations and later expanding his role to include U.K. manufacturing. Baxter employs over 1,000 people in Mayo and a further 200 between its European Financial Shared Services Centre in Dublin and its Sales & Marketing functions in Dublin and Belfast. We have every good reason to feel proud of the role that the Irish medical technology industry plays in advancing patient health and improving the quality and efficiency of health care systems right across the world. Ireland s medtech sector has evolved into one of the leading clusters for medical device and diagnostic products globally. Looking to the future of the medical technology sector globally, we can see that the pace of change in the sector is increasing at an unrelententing speed. Patient demographics, healthcare reform, hospital consolidation, austerity measures, technological change, regulation are but some of the influencers that we are aware of and incorporating into our plans. While challenging for us all, these changing dynamics provide us with enormous opportunities. To make innovation work for us, have to work to develop an ecosystem in which each element, and each interaction, supports the economy and society and we are succeeding. Pat Delaney Director of Sectors, Enterprise and Regional Policy, IBEC Pat Delaney is the director responsible for business sectors, enterprise and regional policy in IBEC. This division provides detailed technical, regulatory and policy representation to over 50 specific industry groups within the Confederation. Prior to being appointed to the Executive Board of the Confederation, Pat was Director of the Small Firms Association from 1998 to He is a member of a number of public bodies including the Social Partnership Plenary Council, the National Competitiveness Council, the Better Regulation Forum, the High Level Group on Manufacturing, the Irish Payments Organisation, and, is a former member of the Pensions Board. The very real strengths and successes of Irish-based businesses have recently tended to get overshadowed given the intense media focus on the fiscal and banking crises. Ireland is in many ways well positioned to take advantage of emerging global trends in the sector; activities located in Ireland are becoming increasingly sophisticated and driven by R&D, and the taxation regime in Ireland is supportive. In terms of bringing order to our public finances necessary for maintaining our economic independence IBEC has two overarching priorities: credible progress on reducing the fiscal deficit and substantive measures to address the jobs crisis. Irish business has the scale and scope needed to generate substantial and sustainable growth and the medtech sector will form an integral part of this.

5 Roland Pfleger Vice President and General Manager, Respiratory and Monitoring Solutions, EMEA Roland Pfleger, is an Austrian national and holds a best honours degree in Economics, from Vienna University (1986), majoring in Advertising, Market Research and Controlling. He is fully bilingual in German and English, and also has a fair knowledge of Portuguese. Pfleger has worked for leading healthcare companies including Eli Lilly, Boston Scientific and currently Covidien. He worked for Eli Lilly between 1988 and During this time, he worked as a financial analyst; a Business Development Manager, Pharmaceutical Division, Eastern Europe; and as the General Manager of Lilly Portugal and became the Controller for Lilly Germany. In August 1997, Pfleger joined Boston Scientific, where he became the CEO of Schneider Europe following its acquisition by Boston Scientific from Pfeizer. He was Director for Strategic Planning before joining Boston Scientific as the General Manager of Germany. Pfleger joined Covidien (or Tyco Healthcare as it was) in August 2003 and was General Manager of Tyco Healthcare Germany. He is now the Vice President and General Manager, Respiratory and Monitoring Solutions, EMEA. In 2010, Pfleger joined the Board of Eucomed, the leading Medical Technology Trade Association in Europe. Bryan Mohally Vice President Supply Chain Operations, Johnson & Johnson Bryan Mohally is currently VP Supply Chain Operations with Johnson & Johnson Inc USA, and is also a board member of several other J&J affiliates in Ireland. Previously for many years he was Managing Director of Janssen Pharmaceutical Ltd, a subsidiary of Johnson & Johnson. He is a Past President of PharmaChemical Ireland, the representative body within IBEC for the pharmaceutical and chemical sector, and he also serves on the Board of Directors of the Cork Cancer Research Centre, a cancer research partnership between U.C.C. and the Cork Hospitals. He has recently served on the Government Innovation Taskforce and currently serves as a member of the Implementation Team. Covidien is a global healthcare company based in Ireland that develops and markets advanced surgical instruments, procedure-enabling devices, patient care and safety products, pharmaceutical products, imaging solutions for the diagnosis and treatment of diseases, and nuclear medicines. Our mission is to innovate and develop new products that improve patient outcomes and enable surgeons and other healthcare professionals to deliver the best possible patient care. Covidien employs 42,000 people worldwide with over 7,000 employees in Europe. Our products are available in over 140 countries. Covidien recently reorganised the global business units to the following: Medical Devices, Pharmaceutical Products, and Medical Supplies. Covidien in Ireland Covidien has a well-established presence in Ireland and has operated in the country for nearly 30 years. We employ almost 2,000 people in Ireland. This is our largest employee base in Europe. Covidien has four manufacturing sites, a sales and customer service operations, and our principal executive office in the country. Tullamore: Medical Supplies Galway: Respiratory and Monitoring Solutions Athlone: Respiratory and Monitoring Solutions Dublin: Imaging Solutions (Damastown) Customer Service Center (Cherrywood) Principal Executive Office (Dublin 2) In 2008, the Government set out the overarching framework for rebuilding and repositioning Ireland as a Smart Economy, and creating The Innovation Island. The Innovation Taskforce was subsequently established to focus on measures to progress one pillar of Building Ireland s Smart Economy : Building the innovation or ideas component of the economy through the utilisation of human capital the knowledge, skills and creativity of people and the ability and effectiveness of that human capital to translate ideas into valuable processes, products and services. The Innovation Taskforce completed its work in March 2010 and published its report, Innovation Ireland Report of the Innovation Taskforce, which provides an important road map for positioning Ireland as an international innovation development hub. A high-level Innovation Taskforce Implementation Committee (ITFIC) was established, chaired by the Minister for Enterprise, Trade and Employment, to oversee implementation of the recommendations outlined in the report.

6 John Elwood Vice President, Global Manufacturing, KCI John Elwood is a University of Limerick graduate with first class honours degree. In Manufacturing Engineering and a Ph.D. in automation. He was the winner of the 2002 MEETA National Maintenance Award and runner up in 2004 Chartered Engineer of the Year Award. Previous Industrial experience includes: Bose, Carrickmacross Several leadership positions with Hewlett Packard s ink-jet division in Leixlip, Co. Kildare General Manager, Celestica, Galway, and KCI. John joined KCI in September 07 as General Manager for KCI s Ireland start-up. He is currently Vice President of Global Manufacturing for KCI s Active Healing Solutions business, with responsibility for global manufacturing, global manufacturing engineering and global procurement. KCI opened its manufacturing facility in Athlone in late Today this facility manufactures a wide range of FDA Class II products. Depending on the product, the volumes range from a few hundred units annually to several million units annually. This presentation focuses on KCI Manufacturing Irelands strategy to automate the manufacturing of its high volume products, and become more cost competitive than KCI s existing low cost supply strategy. Matt McBride Plant Manager, Harmac Medical Products Matt Mc Bride is Plant Manager with Harmac Medical Products Ltd. in Castlerea, Ireland. Matt graduated from Athlone Instititute of Technology in 1982 with a degree in Polymer Science, trained with Tyco Healthcare as a Six Sigma Black Belt and received an MBA from Coventry University in Matt has worked in the Medical Device Industry for over 25 years and has extensive experience in the implementation of Lean Manufacturing, Six Sigma and Automation to eliminate waste and variation to deliver bottom line results. Matt s presentation will briefly outline how Harmac s implementation of Operational Excellence has helped Harmac create competitive advantage for their customers while also delivering significant business improvements at their manufacturing sites. Harmac Medical Products Ltd, is a full-service, vertically integrated, contract medical device company. From concept to design, manufacturing and packaging, Harmac produce high-quality, custom, single-use devices for a global customer base that includes many Fortune 500 companies. Harmac Medical Products were successful in winning the IMDA Gold Award for Operational Excellence in 2009 and this presentation will outline some of the key enablers that have helped Harmac to create competitive advantage for our customers, while also delivering significant internal business improvements, at all our sites.

7 Frank Keane General Manager, Vitalograph Ireland Frank has been General Manager of Vitalograph, Ireland since He was educated at Trinity College and graduated with a B.Eng in Electronic Engineering from UL (1982) and an M.Sc in Management Science. He was previously General Manager of Parthus Technologies GPS Division in Northampton UK and VP of Product marketing for Parthus. Prior to that Frank was Director of Product Marketing and Engineering Manager at Artesyn Technolgies and previous to that he was R&D Manager and Design Engineer at various Midwest Multinationals and indigenous companies. Vitalograph was formed as Garthur in 1963 to develop and market the worlds first Office spirometer. The product was an instant success and the name of the product; the Vitalograph quickly became adopted as the company name. Vitalograph opened in Ireland in 1974 and soon afterwards Ireland became the company s sole R&D and manufacturing facility, which it has remained to this day. Vitalograph s core business is the design, manufacture and marketing of spirometers and associated products. A spirometer is a device used to measure lung function, which is achieved by the subject blowing into the device. Vitalograph is the leader in this niche field and has been for some years. However three other markets have complemented the traditional core market in recent years. The first market is that of consumables such as filters, valves and noseclips. The second market is Clinical Drug Trials where Vitalograph has participated for close to ten years and have become number two in the world in respiratory drug trials. The product here is a combination of hardware, software and services such as data management and project management. The last market is services such as product servicing, technical support and whole product definition items such as training and trainers. The presentation will focus on a change program, initiated at the end of 2005, to substantially change the organisation. It will examine the change processes used, as well as the results of the change, what worked and what didn t. John Power CEO, Aerogen Founder of five hi-tech start-up s, over a thirty year career, John is a passionate innovator in both technology and business. His company Aerogen, based in Galway, is regarded as a world leader in acute care drug delivery having created a range of award winning high performance aerosol therapy products for patients in the ICU setting. Aerogen is today working with its partners to deliver innovative solutions for a broad spectrum of respiratory and systemic conditions and is pioneering the use of its technology to create new markets in both surgical and ophthalmic drug delivery. John holds qualifications in mechanical and production engineering and computer technology along with an MBA from Oxford Brookes University. Aerogen is a specialty medical device and drug delivery company specialising in the design, manufacture, marketing of nebulization systems, aimed at the critical care respiratory market. Aerogen s patented OnQ aerosol technology is an integral part of its drug delivery systems. Founded in Galway in 1997, Aerogen has grown to become the global leader in acute care aerosol drug delivery equipment and today its Aeroneb products play a critical role in treating patients on life-support ventilation, as well as home care offerings in over 50 counties worldwide. Aerogen currently employs a growing team of 40 primarily Science and Engineering graduates, many to PhD level. Aerogen is dynamic and evolving company, focusing on innovative products that create new market opportunities. It is this innovative approach that has seen Aerogen register over 40 international patents and continually develop new products, leading the way in the aerosolized drug delivery market.

8 Medical Technology Industry Excellence Awards 2010 jointly hosted by Enterprise Ireland, IDA Ireland and Irish Medical Devices Association. For more information contact Sinead Keogh; IMDA, Confederation House 84/86 Lwr Baggot St, Dublin 2 Tel: sinead.keogh@ibec.ie